Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cantech Holding's Total Stockholders Equity for the quarter that ended in Sep. 2015 was $-0.86 Mil. Cantech Holding's Total Assets for the quarter that ended in Sep. 2015 was $0.01 Mil.
The historical rank and industry rank for Cantech Holding's Equity-to-Asset or its related term are showing as below:
BSSP's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.68 * Ranked among companies with meaningful Equity-to-Asset only.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Cantech Holding Equity-to-Asset Related Terms
Cantech Holding Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Cantech Holding's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSSP vs HSTC, NTRR, TLOG: Equity-to-Asset Comparison
For the Biotechnology subindustry, Cantech Holding's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cantech Holding Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cantech Holding's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Cantech Holding's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Cantech Holding's Equity to Asset Ratio for the fiscal year that ended in Dec. 2014 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cantech Holding (BSSP) has a Equity-to-Asset of -78.36 as of Sep. 2015. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cantech Holding and its competitors.
Is Cantech Holding's Equity-to-Asset too high?
Cantech Holding's current Equity-to-Asset is -78.36.
How does Cantech Holding's Equity-to-Asset compare to HSTC and NTRR?
Cantech Holding's Equity-to-Asset of -78.36 can be compared against companies in the Biotechnology industry. The industry median Equity-to-Asset is 0.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cantech Holding and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cantech Holding's current Equity-to-Asset is -78.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantech Holding stock overvalued right now?
Cantech Holding (BSSP) has a current Equity-to-Asset of -78.36. The current Equity-to-Asset is -78.36. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Cantech Holding (BSSP), the current Equity-to-Asset is -78.36 as of Sep. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cantech Holding Inc is a development stage immunotherapeutic-based technology company. Principally, it is focused on commercialization of its proprietary proteins for the treatment of cancer and various infectious diseases. Its Irreversible Pepsine Fraction (IPF) is a therapeutic platform technology that can be used to facilitate varieties of applications. The company's product consists of IMMUNE-THERAPEUTIC PROTEIN which is a therapeutic protein isolated from porsine pepsin and is irreversible, modified, and fractionated to the sequence IPF.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSSP has been successfully added to your 
